Our live Investing Matters Podcast Special which took place at the Master Investor Show discussing 'How undervalued is the UK stock market?', has just been released. Listen here.
Totally undervalued. SP at least 30P
Yes I think so. Don't know why this one is down so much. I went through their all reports. But did not find any sold reason behind it. Yes-off course, sales down, last quarter in loss, £13 million loam. But looking at their overall asset. This cap should be at least over £20-£25 Million. which gives the share price at least 30p!!! Totally undervalued.
I got a feel that the next update will not only be about their progress on the trials, but also will be able to have some news on commercialisation, that's why Nigel it taking long time for the update. We need to keep patience and this will boom with the positive news.
https://www.irishpost.com/news/anti-covid-pill-could-replace-jabs-as-green-light-is-given-for-clinical-trials-to-begin-201514
N4p is also doing research about oral vaccine. You never know , if successful this will be multi bug. Just like INM bio which was only $5-$6 range & now it is over $24. All we need is patient. Let’s see what Nigel deliver this time - lot of things to come - Vaccine delivery system , oral vaccine proof of concept update , update on commercial news.
Any positive news will make the SP moving faster with a short time target to 25p.
With the big buy give confidence that - what people expect from it. hugely potential from on. MM was trying to mark it down since morning to fill up this huge buy at 8.30P - 1.2 million share. Apart from some people ( who was trying to de ramp it ) we all know what N4p technology worth - we just need phase 3 trial goes well and laster on commercial news. This one can be next NCYT --with huge potential. Expecting some news by Friday or next week. Tomorrow will be another interesting day- can easily go over 9.50p in the morning.
very much confident about his last few RNS- with the success of the trial - commercialisation is on the card, last placing was seriously over subscribed. So all positive news and last placing was not that bad at 8P. First good news will be the trial result, next to come with the commercialisation this will boost up the share price. Current COVID condition is favourable to N4P and with the good news price can easily move up quickly and depending on the price who know it can gain 200-300% increase in value.
It is the right time to invest here now. Then sit down and see the next rise. According to the last RNS - The placing was significantly over subscribed ( which confirmed it's demand in the market) and also commercialisation is no the card ( if trial goes well).
The important part of the RNS : Whilst we are well funded for all existing work streams these additional funds will enable us to plan for follow on studies and more product focussed experiments as we move towards collaboration.
With the funding they have now will be useful for them to go straight to Collaboration. It’s time to invest here & sit down for the play.
Yes- COVID passport is the only option to track it and one deal is done- CTEA will be more deal to come. Expecting some exciting time from now on.